Quick Takeaways
- PRICE T ROWE ASSOCIATES INC /MD/ filed SCHEDULE 13G/A for MOONLAKE IMMUNOTHERAPEUTICS COMMON STOCK (MLTX).
- Disclosed ownership: 4.7%.
- Date of event: 31 Mar 2025.
PRICE T ROWE ASSOCIATES INC /MD/ - 31 Mar 2025 SCHEDULE 13G/A Report for MOONLAKE IMMUNOTHERAPEUTICS COMMON STOCK (MLTX)
- Filing Manager
- PRICE T ROWE ASSOCIATES INC /MD/
- Reporting Manager
- T. Rowe Price Associates, Inc.
- Symbol
- MLTX
- Shares outstanding
- 63,282,362 shares
- Disclosed Ownership
- 2,974,271 shares
- Ownership
- 4.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 May 2025, 10:45:26 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"PRICE T ROWE ASSOCIATES INC /MD/ disclosed 4.7% ownership in MOONLAKE IMMUNOTHERAPEUTICS COMMON STOCK (MLTX) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 14 May 2025, 10:45.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 4.7% | 2,974,271 | 2,939,443 | 0 | Ellen York | Vice President |